Is Ascendis Pharma A/S (ASND) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.9% / 30% | 4.2% / 30% | 1.1% / 30% | 2.12% / 5% | ✓ HALAL |
| DJIM | 5.9% / 33% | 4.2% / 33% | 1.1% / 33% | 2.12% / 5% | ✓ HALAL |
| MSCI | 66.9% / 33% | 47.3% / 33% | 12.1% / 33% | 2.12% / 5% | ✗ NOT HALAL |
| S&P | 5.9% / 33% | 4.2% / 33% | 1.1% / 33% | 2.12% / 5% | ✓ HALAL |
| FTSE | 66.9% / 33% | 47.3% / 33% | 12.1% / 50% | 2.12% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 86.8% | |
| Operating Margin | 1.0% | |
| Net Margin | -31.7% | |
| Return on Assets (ROA) | -6.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $54M |
| Free Cash Flow | $45M |
| Total Debt | $872M |
| Current Ratio | 1.0 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $220.60 |
| 50-Day MA | $226.51 |
| 200-Day MA | $203.20 |
| Avg Volume | 676K |
| Beta | 0.5 |
|
52-Week Range
$124.06
| |
About Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Purification Calculator
As a halal stock with 2.12% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ascendis Pharma A/S (ASND) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ascendis Pharma A/S is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ascendis Pharma A/S's debt ratio?
Ascendis Pharma A/S's debt ratio is 5.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 66.9%.
Does Ascendis Pharma A/S require dividend purification?
Yes, Ascendis Pharma A/S has an impermissible income ratio of 2.12%, which means 2.12% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Ascendis Pharma A/S's key financial metrics?
Ascendis Pharma A/S has a market capitalization of $13.3B, and revenue of $720M. The company maintains a gross margin of 86.8% and a net margin of -31.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.